1. Home
  2. Knowledge Base
  3. References
  4. Development and evaluation of T-Zap: a novel antibody-drug conjugate for the treatment of Her2 positive breast cancer

Development and evaluation of T-Zap: a novel antibody-drug conjugate for the treatment of Her2 positive breast cancer

Hoffmann RM, Crescioli S, Thurston DE, Karagiannis SN (2018) Development and evaluation of T-Zap: a novel antibody-drug conjugate for the treatment of Her2 positive breast cancer. Cancer Res 78:LB-001. doi: 10.1158/1538-7445.AM2018-LB-001

Objective: Develop and Evaluate a novel ADC (T-Zap) for breast cancer.

Summary: Binding to target cells of T-Zap was confirmed. Comparison of T-Zap efficacy in breast cancer cell lines with and without resistance against trastuzumab showed a trend for higher efficacy of cell killing by T-Zap in trastuzumab resistant cells compared to T-DM1. Toxicity assays revealed no impact of T-Zap on cell viability in immune cells.

Usage: T-ZAP was made using Biotinylated monoclonal antibody tratuzumab mixed with Streptavidin-ZAP.

Related Products: Streptavidin-ZAP (Cat. #IT-27)